GGiantBullStocks

MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)

NASDAQ · Healthcare

$19.05-3.20%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$1.68B
P/E ratio
EPS
Volume
615,386
52-week high
52-week low
Open
$19.95
Day high
$20.29
Day low
$19.02

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025-$227.32M-$3.53
2024-$118.94M-$1.89
2023-$36.01M-$0.73
2022-$49.97M-$1.70
2021-$53.64M-$6.84

About MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

CEO
Jorge Santos da Silva
Employees
130
Country
CH
IPO date
Oct 20, 2020

Similar stocks

Other Healthcare companies

Frequently asked questions

What is MoonLake Immunotherapeutics - Class A Ordinary Shares's stock price today?
MLTX is trading at $19.05 as of Jul 20, 2026.
What is MoonLake Immunotherapeutics - Class A Ordinary Shares's market cap?
MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX) has a market capitalization of $1.68B.
Does MoonLake Immunotherapeutics - Class A Ordinary Shares pay a dividend?
MoonLake Immunotherapeutics - Class A Ordinary Shares did not pay a dividend in its most recent reported fiscal year.
What sector is MoonLake Immunotherapeutics - Class A Ordinary Shares in?
MoonLake Immunotherapeutics - Class A Ordinary Shares operates in the Healthcare sector.